[
  {
    "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
    "bbox": [
      387,
      128,
      945,
      141
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
    "bbox": [
      112,
      161,
      1000,
      173
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
    "bbox": [
      112,
      178,
      1000,
      191
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
    "bbox": [
      112,
      178,
      1000,
      191
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
    "bbox": [
      112,
      161,
      1000,
      173
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
    "bbox": [
      179,
      144,
      1000,
      157
    ],
    "label": 3,
    "category": "Agreement Date"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      81,
      1000,
      92
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
    "bbox": [
      126,
      96,
      1000,
      108
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "competitively harmful if publicly disclosed.",
    "bbox": [
      502,
      113,
      829,
      125
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
    "bbox": [
      387,
      128,
      945,
      141
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
    "bbox": [
      179,
      144,
      1000,
      157
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
    "bbox": [
      112,
      161,
      1000,
      173
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
    "bbox": [
      112,
      178,
      1000,
      191
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "RECITALS",
    "bbox": [
      623,
      196,
      710,
      206
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
    "bbox": [
      179,
      210,
      1000,
      225
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
    "bbox": [
      179,
      227,
      1000,
      240
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
    "bbox": [
      180,
      244,
      1000,
      256
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
    "bbox": [
      112,
      260,
      1000,
      272
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and conditions set forth herein;.",
    "bbox": [
      111,
      275,
      350,
      288
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
    "bbox": [
      178,
      290,
      1000,
      305
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the terms and conditions set forth herein: and.",
    "bbox": [
      112,
      308,
      454,
      318
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
    "bbox": [
      180,
      324,
      1000,
      336
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Date (later defined) occurs..",
    "bbox": [
      113,
      341,
      315,
      351
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
    "bbox": [
      178,
      355,
      1000,
      368
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
    "bbox": [
      110,
      371,
      1000,
      384
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "to be legally bound, hereby agree as follows:",
    "bbox": [
      112,
      388,
      448,
      400
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1. DEFINITIONS.",
    "bbox": [
      113,
      404,
      245,
      414
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
    "bbox": [
      179,
      420,
      1000,
      432
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
    "bbox": [
      180,
      436,
      1000,
      448
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
    "bbox": [
      113,
      453,
      1000,
      465
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
    "bbox": [
      113,
      469,
      758,
      481
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
    "bbox": [
      179,
      485,
      944,
      497
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      81,
      1000,
      92
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
    "bbox": [
      126,
      96,
      1000,
      108
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "competitively harmful if publicly disclosed.",
    "bbox": [
      502,
      113,
      829,
      125
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
    "bbox": [
      387,
      128,
      945,
      141
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
    "bbox": [
      179,
      144,
      1000,
      157
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
    "bbox": [
      112,
      161,
      1000,
      173
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
    "bbox": [
      112,
      178,
      1000,
      191
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "RECITALS",
    "bbox": [
      623,
      196,
      710,
      206
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
    "bbox": [
      179,
      210,
      1000,
      225
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
    "bbox": [
      179,
      227,
      1000,
      240
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
    "bbox": [
      180,
      244,
      1000,
      256
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
    "bbox": [
      112,
      260,
      1000,
      272
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "and conditions set forth herein;.",
    "bbox": [
      111,
      275,
      350,
      288
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
    "bbox": [
      178,
      290,
      1000,
      305
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the terms and conditions set forth herein: and.",
    "bbox": [
      112,
      308,
      454,
      318
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
    "bbox": [
      180,
      324,
      1000,
      336
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Date (later defined) occurs..",
    "bbox": [
      113,
      341,
      315,
      351
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
    "bbox": [
      178,
      355,
      1000,
      368
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
    "bbox": [
      110,
      371,
      1000,
      384
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "to be legally bound, hereby agree as follows:",
    "bbox": [
      112,
      388,
      448,
      400
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1. DEFINITIONS.",
    "bbox": [
      113,
      404,
      245,
      414
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
    "bbox": [
      179,
      420,
      1000,
      432
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
    "bbox": [
      180,
      436,
      1000,
      448
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
    "bbox": [
      113,
      453,
      1000,
      465
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
    "bbox": [
      113,
      469,
      758,
      481
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
    "bbox": [
      179,
      485,
      944,
      497
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Exhibit 10.1",
    "bbox": [
      1000,
      81,
      1000,
      92
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Certain information identified by bracketed asterisks (I * * * 1) has been omitted from this exhibit because it is both not material and would be",
    "bbox": [
      126,
      96,
      1000,
      108
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "competitively harmful if publicly disclosed.",
    "bbox": [
      502,
      113,
      829,
      125
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT",
    "bbox": [
      387,
      128,
      945,
      141
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "THIS EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT (this \"Agreement') is entered into as of June 12, 2019 (the",
    "bbox": [
      179,
      144,
      1000,
      157
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "\"Execution Date') by and between Eton Pharmaceuticals, Inc., a Delaware corporation with offices at 21925 W. Field Pkwy, Suite 235, Deer Park,",
    "bbox": [
      112,
      161,
      1000,
      173
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Illinois, USA (\"ETON), and Aucta Pharmaceuticals, Inc., a Delaware corporation with offices at 71 Suttons Lane, Piscataway, NJ O8854 (\"Aucta') .",
    "bbox": [
      112,
      178,
      1000,
      191
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "RECITALS",
    "bbox": [
      623,
      196,
      710,
      206
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, ETON is engaged in the business of licensing, developing, marketing, distributing and selling pharmaceutical drug products;.",
    "bbox": [
      179,
      210,
      1000,
      225
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, Aucta is engaged in the business of developing pharmaceutical drug products, including the Products (later defined);.",
    "bbox": [
      179,
      227,
      1000,
      240
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, ETON desires to obtain an exclusive license to the Products, the Dossiers (later defined), and Aucta Background Intellectual",
    "bbox": [
      180,
      244,
      1000,
      256
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Property (later defined) for Marketing the Products in the Territory, and Aucta is willing to grant such an exclusive license to ETON under the terms",
    "bbox": [
      112,
      260,
      1000,
      272
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "and conditions set forth herein;.",
    "bbox": [
      111,
      275,
      350,
      288
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, ETON will pay Aucta certain milestone, royalty and licensing payments based on the sale of Products in the Territory under.",
    "bbox": [
      178,
      290,
      1000,
      305
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the terms and conditions set forth herein: and.",
    "bbox": [
      112,
      308,
      454,
      318
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, the parties hereto agree that, unless otherwise stated, the terms herein shall not be effective unless and until the Effective",
    "bbox": [
      180,
      324,
      1000,
      336
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Date (later defined) occurs..",
    "bbox": [
      113,
      341,
      315,
      351
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements herein",
    "bbox": [
      178,
      355,
      1000,
      368
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ETON and Aucta, intending",
    "bbox": [
      110,
      371,
      1000,
      384
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "to be legally bound, hereby agree as follows:",
    "bbox": [
      112,
      388,
      448,
      400
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1. DEFINITIONS.",
    "bbox": [
      113,
      404,
      245,
      414
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below:",
    "bbox": [
      179,
      420,
      1000,
      432
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.1 \"Affiliates' means, with respect to a Party or any Third Party, any corporation, firm, partnership or other entity that controls, is",
    "bbox": [
      180,
      436,
      1000,
      448
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "controlled by or is under common control with such entity. For the purposes of this definition, \"control\"' means the ownership of at least 50% of the",
    "bbox": [
      113,
      453,
      1000,
      465
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "voting share capital of an entity or any other comparable equity or ownership interest..",
    "bbox": [
      113,
      469,
      758,
      481
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.2 \"ANDA Litigation\" shall have the meaning ascribed to the term in Section 7.5.2 of this Agreement.",
    "bbox": [
      179,
      485,
      944,
      497
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: ETON PHARMACEUTICALS, INC., 10-Q, 11/14/2019",
    "bbox": [
      133,
      1000,
      606,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  }
]